DAOIB for the Treatment of Brain Fog

Chang Gung Medical Foundation

Status and phase

Enrolling

Phase 2

Conditions

Long COVID

Treatments

Drug: DAOIB

Study type

Interventional

Funder types

Other

Identifiers

NCT05764538

202200988A3

Details and patient eligibility

About

This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

"post-COVID-19 condition" defined by WHO (symptoms present at three months after SARS-CoV-2 infection and last for at least 2 months which cannot be explained by an alternative diagnosis)(Cabrera Martimbianco, Pacheco et al. 2021) and COVID-induced cognitive impairments
physically healthy and have all laboratory assessments (including urine/blood routine, biochemical tests, and electrocardiograph) within normal limits
have sufficient education to communicate effectively and are capable of completing the assessments of the study

Exclusion criteria

history of significant cerebrovascular disease
Hachinski Ischemic Score > 4
major neurological, psychiatric or medical conditions other than long COVID-induced cognitive impairments
memantine use (memantine is an NMDAR partial antagonist)
substance (including alcohol) abuse or dependence
delusion, hallucination or delirium symptoms
severe visual or hearing loss
inability to follow the protocol